| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London.
1. The function of angiotensin converting enzyme was investigated in twenty-four healthy men. Forearm blood flow was measured under basal conditions and during administration of enalaprilat (a converting enzyme inhibitor) and/or peptide substrates of converting enzyme into the left brachial artery. Blood flow was compared in the two arms. 2. Enalaprilat had no effect on basal blood flow. The concentration of enalaprilat in venous blood from the control arm was low, and plasma renin activity was not increased, indicating that systemic inhibition of converting enzyme did not occur. 3. Effects of angiotensin and of bradykinin, administered intra-arterially, were limited to the infused arm. Enalaprilat (13 nmol min-1) inhibited converting enzyme in the infused arm, in which it caused approximately a 100-fold reduction in sensitivity to angiotensin I, while having no effect on the vasoconstriction caused by angiotensin II. Enalaprilat increased vasodilatation caused by bradykinin. 4. Aspirin, an inhibitor of cyclo-oxygenase, did not inhibit vasodilatation caused by bradykinin whether infused alone or with enalaprilat, indicating that these responses are not mediated by prostaglandins. 5. We conclude that under basal conditions neither conversion of angiotensin I to angiotensin II nor degradation of bradykinin determines resistance vessel tone in the human forearm. Converting enzyme may affect vascular tone in situations in which intravascular concentrations of peptides are increased over those present under basal conditions.
This article has been cited by other articles:
|
|
 |
|
  R. Dwivedi, S. Saha, P.J. Chowienczyk, and J.M. Ritter Block of Inward Rectifying K+ Channels (KIR) Inhibits Bradykinin-Induced Vasodilatation in Human Forearm Resistance Vasculature Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): e7 - e9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Goddard, C. Eckhart, N. R. Johnston, A. D. Cumming, A. J. Rankin, and D. J. Webb Endothelin A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Are Synergistic via an Endothelin B Receptor-Mediated and Nitric Oxide-Dependent Mechanism J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2601 - 2610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L.M. Cruden, F. N. Witherow, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1043 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Leslie, T. Attina, E. Hultsch, L. Bolscher, M. Grossman, M. A. Denvir, and D. J. Webb Comparison of two plethysmography systems in assessment of forearm blood flow J Appl Physiol, May 1, 2004; 96(5): 1794 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Chan, P. Vallance, and H. M. Colhoun Endothelium-Dependent and -Independent Vascular Dysfunction in Type 1 Diabetes: Role of Conventional Risk Factors, Sex, and Glycemic Control Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1048 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance Protease-Activated Receptor 2-Mediated Vasodilatation in Humans In Vivo: Role of Nitric Oxide and Prostanoids Circulation, February 25, 2003; 107(7): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, D. Rosenbaum, D. E. Vaughan, and N. J. Brown Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin Circulation, February 4, 2003; 107(4): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dawes, C. Sieniawska, T. Delves, R. Dwivedi, P. J. Chowienczyk, and J. M. Ritter Barium Reduces Resting Blood Flow and Inhibits Potassium-Induced Vasodilation in the Human Forearm Circulation, March 19, 2002; 105(11): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. J. Farquharson and A. D. Struthers Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure J. Am. Coll. Cardiol., March 6, 2002; 39(5): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, D. A. Rosenbaum, J. Lefebvre, D. E. Vaughan, and N. J. Brown Smoking Impairs Bradykinin-Stimulated t-PA Release Hypertension, March 1, 2002; 39(3): 767 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Labinjoh, D. E. Newby, M. P. Pellegrini, N. R. Johnston, N. A. Boon, and D. J. Webb Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1402 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Witherow, A. Helmy, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Circulation, October 30, 2001; 104(18): 2177 - 2181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Clive, D. J. Webb, A. MacLellan, A. Young, B. Byrne, L. Robson, J. F. Smyth, and D. I. Jodrell Forearm Blood Flow and Local Responses to Peptide Vasodilators: A Novel Pharmacodynamic Measure in the Phase I Trial of Antagonist G, a Neuropeptide Growth Factor Antagonist Clin. Cancer Res., October 1, 2001; 7(10): 3071 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown, J. V. Gainer, L. J. Murphey, and D. E. Vaughan Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor-Dependent, NO Synthase-Independent, and Cyclooxygenase-Independent Pathway Circulation, October 31, 2000; 102(18): 2190 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Labinjoh, D. E. Newby, P. Dawson, N. R. Johnston, C. A. Ludlam, N. A. Boon, and D. J. Webb Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man Cardiovasc Res, September 1, 2000; 47(4): 707 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Davie and J. J. V. McMurray Effect of Angiotensin-(1-7) and Bradykinin in Patients With Heart Failure Treated With an ACE Inhibitor Hypertension, September 1, 1999; 34(3): 457 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Davie, H. J. Dargie, and J. J. V. McMurray Role of Bradykinin in the Vasodilator Effects of Losartan and Enalapril in Patients With Heart Failure Circulation, July 20, 1999; 100(3): 268 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, S. Husain, and A. A. Quyyumi Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin J. Am. Coll. Cardiol., March 1, 1999; 33(3): 796 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E Newby, S. Masumori, N. R Johnston, N. A Boon, and D. J Webb Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man Cardiovasc Res, November 1, 1997; 36(2): 268 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Haefeli, L. Linder, and T. F. Luscher Quinaprilat Induces Arterial Vasodilation Mediated by Nitric Oxide in Humans Hypertension, October 1, 1997; 30(4): 912 - 917. [Abstract] [Full Text]
|
|
|
|
|
|
W. G. Haynes, C. J. Ferro, K. P. J. O'Kane, D. Somerville, C. C. Lomax, and D. J. Webb Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans Circulation, May 15, 1996; 93(10): 1860 - 1870. [Abstract] [Full Text]
|
|
|
|
|
|
N. C. Davidson, C. S. Barr, and A. D. Struthers C-Type Natriuretic Peptide : An Endogenous Inhibitor of Vascular Angiotensin-Converting Enzyme Activity Circulation, March 15, 1996; 93(6): 1155 - 1159. [Abstract] [Full Text]
|
|
|
|
|
|
K. Bhagat, J. Collier, and P. Vallance Vasodilatation to Arachidonic Acid in Humans : An Insight Into Endogenous Prostanoids and Effects of Aspirin Circulation, October 15, 1995; 92(8): 2113 - 2118. [Abstract] [Full Text]
|
|
|
|
|
|
N. Benjamin, A. Calver, J. Collier, B. Robinson, P. Vallance, and D. Webb Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators Hypertension, May 1, 1995; 25(5): 918 - 923. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Panza, C. E. Garcia, C. M. Kilcoyne, A. A. Quyyumi, and R. O. Cannon III Impaired Endothelium-Dependent Vasodilation in Patients With Essential Hypertension : Evidence That Nitric Oxide Abnormality Is Not Localized to a Single Signal Transduction Pathway Circulation, March 15, 1995; 91(6): 1732 - 1738. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
